Sex Differences in Treatment Response to Nucleos(t)ide Therapy in Chronic Hepatitis B: A Multicenter Longitudinal Study
Clinical Gastroenterology and Hepatology · 2024
DOI: 10.1016/j.cgh.2023.09.002 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Clinical Gastroenterology and Hepatology, 2024. Verfasst von Angela Chau und 43 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, Stanford University Medical Center, Palo Alto, California. Hauptthemen laut MEDLINE: Hepatitis B, Chronic, Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: Stanford University.
Abstract (Originalsprache)
BACKGROUND & AIMS: It is unclear if there may be sex differences in response to nucleos(t)ide analogs including virologic response (VR), biochemical response (BR), complete response (CR), and hepatocellular carcinoma (HCC) incidence among hepatitis B patients. We compared nucleos(t)ide analog treatment outcomes by sex. METHODS: We performed a retrospective cohort study of 3388 treatment-naïve adult hepatitis B patients (1250 female, 2138 male) from the Real-World Evidence from the Global Alliance for the Study of Hepatitis B Virus consortium who initiated therapy with either entecavir or tenofovir from 22 sites (Argentina, Korea, Japan, Taiwan, and the United States). We used propensity-score matching to balance background characteristics of the male and female groups and competing-risks analysis to estimate the incidence and subdistribution hazard ratios (SHRs) of VR, BR, CR, and HCC. RESULTS: Females (vs males) were older (52.0 vs 48.6 y); less likely to be overweight/obese (49.3% vs 65.7%), diabetic (9.9% vs 13.1%), or cirrhotic (27.9% vs 33.0%); and had a lower HBV DNA level (5.9 vs 6.0 log10 IU/mL) and alanine aminotransferase level (91 vs 102 IU/L) (all P < .01). However, after propensity-score matching, relevant background characteristics were balanced between the 2 groups. Females (vs males) had similar 5-year cumulative VR (91.3% vs 90.3%; P = .40) and HCC incidence rates (5.1% vs 4.4%; P = .64), but lower BR (84.0% vs 90.9%; P < .001) and CR (78.8% vs 83.4%; P = .016). Males were more likely to achieve BR (SHR, 1.31; 95% CI, 1.17-1.46; P < .001) and CR (SHR, 1.16; 95% CI, 1.03-1.31; P = .016), but VR and HCC risks were similar. CONCLUSIONS: Sex differences exist for treatment outcomes among hepatitis B patients. Male sex was associated with a 16% higher likelihood of clinical remission and a 31% higher likelihood of biochemical response than females, while virologic response and HCC incidence were similar between the 2 groups.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Gastroenterology and Hepatology, Stanford University Medical Center, Palo Alto, California.
- Hepatobiliary Section, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan; Hepatitis Research Center, College of Medicine and Cohort Research Center,…
- Division of Gastroenterology and Hepatology, Department of Medicine, National University Hospital, Singapore; Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
- Department of Internal Medicine, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang, China.
- San Jose Gastroenterology, San Jose, California.
- Department of Internal Medicine, Hanyang University Hospital, Hanyang University College of Medicine, Seoul, Korea; Department of Internal Medicine, Sanggye Paik Hospital, Inje University College of Medicine, Seoul, Kor…
Förderung
- Stanford University
Zitieren
APA
Chau, A., Yeh, M. L., Tsai, P. C., Huang, D. Q., Kim, S. E., Trinh, H., Yoon, E. L., Oh, H., Jeong, J. Y., Ahn, S. B., An, J., Tseng, C. H., Hsu, Y. C., Jeong, S. W., Cho, Y. K., Shim, J. J., Kim, H. S., Ito, T., Marciano, S., …, & Nguyen, M. H. (2024). Sex Differences in Treatment Response to Nucleos(t)ide Therapy in Chronic Hepatitis B: A Multicenter Longitudinal Study. Clinical Gastroenterology and Hepatology. https://doi.org/10.1016/j.cgh.2023.09.002
Vancouver
Chau A, Yeh ML, Tsai PC, Huang DQ, Kim SE, Trinh H, et al. Sex Differences in Treatment Response to Nucleos(t)ide Therapy in Chronic Hepatitis B: A Multicenter Longitudinal Study. Clinical Gastroenterology and Hepatology. 2024. doi:10.1016/j.cgh.2023.09.002
BibTeX
@article{Chau2024,
author = {Chau, Angela and Yeh, Ming-Lun and Tsai, Pei-Chien and Huang, Daniel Q and Kim, Sung Eun and Trinh, Huy and Yoon, Eileen L and Oh, Hyunwoo and Jeong, Jae Yoon and Ahn, Sang Bong and An, Jihyun and Tseng, Cheng-Hao and Hsu, Yao-Chun and Jeong, Soung Won and Cho, Yong Kyun and Shim, Jae-Jun and Kim, Hyoung Su and Ito, Takanori and Marciano, Sebastián and Kawashima, Keigo and Suzuki, Takanori and Watanabe, Tsunamasa and Nozaki, Akito and Ishikawa, Toru and Inoue, Kaori and Eguchi, Yuichiro and Uojima, Haruki and Abe, Hiroshi and Takahashi, Hirokazu and Chuma, Makoto and Ishigami, Masatoshi and Hoang, Joseph K and Maeda, Mayumi and Huang, Chung-Feng and Gadano, Adrian and Dai, Chia-Yen and Huang, Jee-Fu and Tanaka, Yasuhito and Chuang, Wan-Long and Lim, Seng Gee and Cheung, Ramsey and Yu, Ming-Lung and Jun, Dae-Won and Nguyen, Mindie H},
title = {Sex Differences in Treatment Response to Nucleos(t)ide Therapy in Chronic Hepatitis B: A Multicenter Longitudinal Study},
journal = {Clinical Gastroenterology and Hepatology},
year = {2024},
doi = {10.1016/j.cgh.2023.09.002}
}
EUVIMED